Molecular Pharmaceutics
Brief Name:
Mol. Pharmaceutics
Impact factor:
4.5 (2023)
ISSN:
1543-8384
Home Page:
Open Access:
No
Publisher:
American Chemical Society
Publication Frequency:
Monthly
Publication Start Year:
2004
Annual Articles:
460
Self-citation Rate:
6.7%
Chinese Academy of Sciences SCI Journal Classification:
| Major category | Ｍinor category | TOP journal | Ｒeview journal |
|---|---|---|---|
Q2 MEDICAL |
MEDICINE: RESEARCH AND EXPERIMENT | No | No |
Subject Classification:
MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore:
| CiteScore | SJR | SNIP | CiteScore ranking | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 8 | 0.94 | 0.981 |
|
H-Index:
110
SCI Index Status:
Science Citation Index Expanded
Official Review Time:
Submission to First Editorial Decision (Median Days): 4.1
Submission to First Decision with Peer Review (Median Days): 34.8
Submission to Accept (Median Days): 88.3
Accept to ASAP Publication (Median Days): 14
PubMed Central:
Submission Site:
Aims and Scope:
Molecular Pharmaceutics publishes original theoretical and experimental research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. Modalities of interest include small molecules, imaging agents, proteins, peptides, vaccines, cell and gene-based therapies, and their characterization, formulation, and delivery. Scientific areas within the scope of the journal include:
Modelling and simulation to aid mechanistic insights into drug delivery
Molecular understanding of formulations
Formulation performance under physiological conditions
Materials science as it relates to drug, excipients and drug delivery system efficacy.
Emerging techniques and technologies for drug delivery including theranostics, precision medicine and artificial intelligence
Submission of a manuscript to Molecular Pharmaceutics implies that the same work has not been previously published, including as part of a public electronic database (preprint servers like bioRxiv and ChemRxiv are permissible), and is not under consideration for publication elsewhere. In addition, there must be no legal restrictions to publication, e.g., patent activities, at the time of submission.
Modelling and simulation to aid mechanistic insights into drug delivery
Molecular understanding of formulations
Formulation performance under physiological conditions
Materials science as it relates to drug, excipients and drug delivery system efficacy.
Emerging techniques and technologies for drug delivery including theranostics, precision medicine and artificial intelligence
Submission of a manuscript to Molecular Pharmaceutics implies that the same work has not been previously published, including as part of a public electronic database (preprint servers like bioRxiv and ChemRxiv are permissible), and is not under consideration for publication elsewhere. In addition, there must be no legal restrictions to publication, e.g., patent activities, at the time of submission.
Submission Guidelines:
Types of Articles Accepted:
Research Articles
Reviews
Perspectives
Communications
Editorials
Reviews
Perspectives
Communications
Editorials
Submission template:
Reference Citations Format:
Disclaimer:
This page displays information about journals or magazines for reference and study purposes only. It is not the official website of any journal or magazine and does not involve publishing matters. Users must verify any publishing-related inquiries directly with the publisher.
If there are any issues with the content displayed on this page, please contact us at: [email protected], and we will verify and address the matter diligently.
This page displays information about journals or magazines for reference and study purposes only. It is not the official website of any journal or magazine and does not involve publishing matters. Users must verify any publishing-related inquiries directly with the publisher.
If there are any issues with the content displayed on this page, please contact us at: [email protected], and we will verify and address the matter diligently.